The purpose of this study was to detect the efficacy and safety of tacrolimus (TAC) in induction therapy of patients with lupus nephritis. Methods: Associated studies were extracted from the PubMed and the Cochrane Library on July 10, 2018, and applicable investigations were pooled and analyzed by meta-analysis. Data on complete remission (CR), total remission (TR; complete plus partial remission), proteinuria levels, urine erythrocyte number, albumin, glomerular filtration rate, negative rate of ds-DNA, C 3 levels, C 4 levels, systemic lupus erythematosus disease activity index (SLE-DAI), etc, were extracted and pooled using RevMan 5.3. Results: In the therapeutic regimen of TAC + glucocorticoids (GC) vs cyclophosphamide (CYC) + GC, the results indicated that the TAC group had high values of CR, TR, albumin, and negative rate of ds-DNA, and low values of proteinuria levels and SLE-DAI when compared with those in CYC group (all P,0.05). In the therapeutic regimen comprising TAC + GC vs mycophenolate mofetil (MMF) + GC, the results indicated that the difference of CR, TR, proteinuria levels, and albumin between TAC group and MMF group were not significant (all P.0.05). In the therapeutic regimen comprising TAC + MMF + GC vs CYC + GC, multitarget therapy group showed higher values of CR, TR, urinary protein decline, and rise of serum albumin when compared with CYC group (all P,0.05). Conclusion: TAC is an effective and safe agent in induction therapy of patients with lupus nephritis.
Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which autoantibodies target a variety of self-antigens, 1 and persistent disease activity is associated with increased morbidity and mortality. Immune activation of T-helper cells and B cells takes part in the pathogenesis, and endogenous antigens are generated. 2, 3 To clear the antigens, the immune system produces the autoantibodies, which induces tissue inflammation and multiorgan inflammation, especially in kidney. 4, 5 Lupus nephritis is one of the most serious complications of SLE and occurs in up to 60% of patients worldwide; among them, 50%-80% are pediatric-onset SLE cases. [6] [7] [8] [9] Without drug intervention, long-term inflammation may cause irreversible damage to kidney and may cause chronic kidney disease, which subsequently develops into end-stage renal disease.
Traditional therapy for SLE involved the combination of glucocorticoids (GC) with cyclophosphamide (CYC), which was found to be effective in improving long-term prognosis. However, its application was limited because of severe adverse effects, including TAC has a long history in kidney transplantation. As a calcineurin inhibitor, it hinders T-cell activation by inhibiting the calcium/calmodulin-dependent phosphatase calcineurin and combining with FKBP12. 5, 12 It also results in the decrease of IL-2, IL-4, IL-5, IFN-γ, and TNF-α. 9, 13 In the past years, some clinical trials were conducted to explore whether the use of TAC can lead to a better remission of lupus nephritis.
The update of immunosuppressive drugs helps not only in increasing the long-term survival rate of the patients but also in decreasing the associated side effects of corticosteroids. 12, 14 Thus, we performed a systematic review and meta-analyses to assess the efficacy and safety of TAC in induction therapy of patients with lupus nephritis.
Materials and methods search strategy
Systematic searches were performed in the Cochrane Library and PubMed without language limitations from when the database is created to July 10, 2018 using the search terms: (tacrolimus OR FK506 OR TAC) AND (systemic lupus erythematosus OR systemic lupus erythematous OR lupus nephritis OR lupus glomerulonephritis OR lupus nephropathy). We also checked the references cited in the recruited articles for additional reports.
Inclusion and exclusion criteria inclusion criteria
The inclusion criteria for this study were as follows: 1) study type: randomized controlled trials, open-label prospective studies, case-control studies, observational studies, and cohort studies; 2) object of the study: all patients regardless of race who met the diagnostic criteria only for lupus nephritis; 3) interventions: TAC for treatment; and 4) baseline information: TAC was compared with placebo or other drugs.
exclusion criteria
Exclusion criteria for the study were as follows: 1) case reports, reviews, letters, systematic reviews, and meta-analysis;
2) studies that did not include different therapeutic regimens; and 3) the diagnostic criteria were not clear.
Outcome measures
Efficacy of TAC: complete remission (CR), total remission (TR; total CR plus partial remission [PR] ), proteinuria levels, urine erythrocyte number, albumin, glomerular filtration rate (GFR), negative rate of ds-DNA, C 3 levels, C 4 levels, systemic lupus erythematosus disease activity index (SLE-DAI), urinary protein decline, and rise of serum albumin.
Safety of TAC: gastrointestinal syndrome, leucopenia, hypertension, hyperglycemia, infection, pneumonia, upper respiratory infection, urinary tract infection, herpes zoster or varicella, alopecia, irregular menstruation, increase in blood creatinine levels, and liver function disorder.
Data collection
According to the predetermined inclusion criteria, two reviewers scanned the titles and abstracts of the included studies or read the full text to screen for possible relevant literature. Discordant opinions were discussed and resolved by other reviewers. Only randomized controlled trials, randomized cross-over studies, and prospective studies that were related to TAC treatment were included in the analysis.
statistical analysis
The data were extracted from the included literature and Review Manager version 5.3 software was used to pool the results. Heterogeneity was quantified using I 2 statistics and explored for all the meta-analyses. On the basis of the test of heterogeneity, when the P-value $0.1, a fixed-effects model was used. Otherwise, the results were pooled using a random-effects model. Continuous data were expressed using weighted mean differences (WMDs), and binary data were expressed using the OR. 95% CIs were calculated for the included studies with the Mantel-Haenszel (M-H) method. A P-value ,0.05 was regarded as statistical significance.
Results

search results
In this meta-analysis, 13 clinical trials [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] were related to TAC for lupus nephritis (Table 1) . There were 12 randomized controlled studies and one 21 prospective study (Table 1) .
study of the therapeutic regimen of Tac + gc vs cYc + gc Seven studies [16] [17] [18] 21, 22, 24, 25 were included into the metaanalysis to assess the efficacy of TAC in patients with lupus nephritis. In the therapeutic regimen of TAC + GC The dosage was adjusted to achieve a whole blood Tac concentration of 6-8 ng/ml when induction therapy was required, 4-6 ng/ml when maintenance therapy was required, and 4.0 ng/ml when serum creatinine was more than 133 mmol/l and gFr was less than 40 ml/min/1.73 m 2 .
For the cYc group, the protocol was pulse cYc at a dose of 750 mg/m 2 every month for 6 months followed by aZa (100 mg/d) for 6 months. Patients aged from 18 to 65 years, and had a diagnosis of class iii, iV, V, iii 10 mg for at least 8 weeks prior to administration of the study drug, and the attending physician had judged that it was difficult to reduce the dose to below 10 mg/d because of the possibility of recurrence. sixty-three patients were assigned randomly to the Tac group or the placebo group and were treated with oral Tac (3 mg/d) or placebo once daily after dinner for 28 weeks. after starting the trial, the gc dose could not be increased, although tapering was allowed.
63 patients were included, and had a diagnosis of class ii, iii, iV, Figure 1 and Table 2) , and low values of proteinuria levels (WMD =-0.68, 95% CI: -1.21 to -0.15, P=0.01; Table 2 ) and SLE-DAI (OR =-2.00, 95% CI: -3.1 to -0.85, P=0.0007; Figure 1 and Table 2 ) when compared with those in CYC group. However, the differences in urine erythrocyte number, GFR, C 3 levels, and C 4 levels were not significant between TAC + GC group and CYC + GC group ( Table 2 ). The safety of TAC was also assessed in patients with lupus nephritis. In this meta-analysis, the incidence rates of gastrointestinal syndrome (OR =0.30, 95% CI: 0.12-0.78, P=0.01; Table 3 ) in TAC + GC group were lower than those in CYC + GC group. The incidence rates of infection, upper respiratory infection, pneumonia, urinary tract infection, alopecia, and liver function disorder in TAC + GC group were lower than those in CYC + GC group, although there were no statistical differences between the groups (Table 3) . However, the incidence rates of hypertension, hyperglycemia, herpes zoster or varicella, and increase in blood creatinine levels in TAC + GC group were higher than those in CYC + GC group, although there were no statistical differences between the groups (Table 3) . study of the therapeutic regimen of Tac + gc vs MMF + gc Three studies 18, 20, 23 were included into the meta-analysis to assess the efficacy of TAC in patients with lupus nephritis with the therapeutic regimen of TAC + GC vs MMF + GC, and the results indicated that the differences in CR, TR, proteinuria levels, and albumin levels between TAC + GC group and MMF + GC group were not statistically significant Figure 2 and Table 2 ).
The safety of TAC was also assessed in patients with lupus nephritis. In this meta-analysis, the incidence rate of herpes zoster or varicella in TAC + GC group was lower than that in MMF + GC group (OR =0.13, 95% CI: 0.03-0.53, P=0.004; Table 3 ). However, the incidence rate of blood creatinine increase in TAC + GC group was higher than that in MMF + GC group (OR =0.13, 95% CI: 0.03-0.53, P=0.004; Table 3 ). The incidence rates of leucopenia, infection, and serious infection in TAC + GC group were lower than those in MMF + GC group, although there were no statistical differences (Table 3) . However, the incidence rate of hyperglycemia in TAC + GC group was higher than that in MMF + GC group, although there was no statistically significant difference (Table 3) . study of the therapeutic regimen of Tac + MMF + gc vs cYc + gc Two studies 15, 19 were included into the meta-analysis to assess the efficacy of TAC in patients with lupus nephritis with the therapeutic regimen of TAC + MMF + GC vs CYC + GC, the results indicated that the differences of TR, urinary protein decline, and rise of serum albumin between TAC + GC group and MMF + GC group were notable (TR: OR =3.32, 95% CI: 2.08-5.32, P,0.00001; urinary protein decline: WMD =-0.90, 95% CI: -1.40 to -0.40, P=0.0004; rise of serum albumin: WMD =1.96, 95% CI: 0.63-3.29, P=0.004; Figure 3 and Table 2 ). The TAC + MMF + GC group showed high CR rate (OR =5.13, 95% CI: 0.75-35.02, P=0.10) and negative rate of ds-DNA (OR =1.67, 95% CI: 1.00-2.79, P=0.05), although there were no statistical differences ( Figure 3 and Table 2 ).
The safety of TAC was also assessed in patients with lupus nephritis. In this meta-analysis, the incidence rates of gastrointestinal syndrome (OR =0.16, 95% CI: 0.08-0.35, P,0.00001; Table 3 ) in TAC + MMF + GC group were lower than those in CYC + GC group. In this meta-analysis, the incidence rate of hypertension (OR =3.15, 95% CI: 1.06-9.29, P=0.04; Table 3 ) in TAC + MMF + GC group was higher than that in CYC + GC group. The incidence rates of upper respiratory infection, urinary tract infection, and alopecia in TAC + MMF + GC group were lower than those in CYC + GC group, although there were no statistical differences (Table 3) . However, the incidence rates of hyperglycemia, pneumonia, and herpes zoster or varicella in TAC + MMF + GC group were higher than those in CYC + GC group, although there were no statistical differences (Table 3) .
Discussion
In the therapeutic regimen of TAC + GC vs CYC + GC, the results indicated that TAC + GC group had high values of CR, TR, albumin, and negative rate of ds-DNA, and low values of proteinuria levels and SLE-DAI when compared with those in CYC + GC group. In this meta-analysis for Abbreviations: Tac, tacrolimus; gc, glucocorticoids; MMF, mycophenolate mofetil; cYc, cyclophosphamide; cr, complete remission; Tr, total remission, complete plus partial remission; SLE-DAI, systemic lupus erythematosus disease activity index; GFR, glomerular filtration rate; WMD, weighted mean difference. adverse events, the TAC + GC treatment showed lower incidence rates of gastrointestinal syndrome, leucopenia, and irregular menstruation than the CYC + GC treatment. The TAC + GC treatment also showed lower incidence rates of infection, upper respiratory infection, pneumonia, urinary tract infection, alopecia, and liver function disorder when compared with the CYC + GC treatment. However, the TAC + GC treatment showed higher incidence rates of hypertension, hyperglycemia, herpes zoster or varicella, and blood creatinine level increase when compared with the CYC + GC treatment. In a previous study, Chen et al 28 included six studies into the meta-analysis and reported that TAC was superior to CYC in terms of CR rate, TR rate, and anti-dsDNA negative conversion rate. TAC was also associated with less adverse events of gastrointestinal syndrome and amenorrhea than CYC. Kraaij TAC in combination with steroids, and reported that TACbased induction treatment led to a significantly higher total renal response. Our meta-analysis included more studies and assessed more indicators than the previous meta-analyses.
In the therapeutic regimen of TAC + GC vs MMF + GC of our meta-analysis, the results indicated that the differences in CR, TR, proteinuria levels, and albumin between TAC + GC group and MMF + GC group were not statistically different.
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The incidence rate of herpes zoster or varicella in TAC + GC group was lower than that in MMF + GC group. However, the incidence rate of blood creatinine increase in TAC + GC group was higher than that in MMF + GC group. In a previous study, Chen et al 28 included six studies into the meta-analysis and reported that, in the induction therapy of LN, TAC and MMF were more effective and safer when compared with CYC, but there were no differences of efficacy (CR, TR, proteinuria levels) or safety (major infection, serious infection) between the two treatments. Our meta-analysis included more studies and assessed more indicators than the previous meta-analyses.
We also assessed the multitarget therapy (including the TAC) for induction treatment of lupus nephritis, and reported that the differences in TR, urinary protein decline, and rise of serum albumin between TAC + GC group and MMF + GC group were notable. The TAC + MMF + GC group shows high CR rate and negative rate of ds-DNA. Calcineurin inhibitors, including TAC and cyclosporine A, inhibit T-cell proliferation by binding to cyclophilin and inhibiting calcineurin phosphatase activity, thus blocking the activation of T-cellspecific transcription factors. 30, 31 MMF, when hydrolyzed to the active drug mycophenolic acid, is a potent inhibitor of the proliferation of T and B lymphocytes via reversible inhibition of inosine 5-monophosphate dehydrogenase. 30 CYC can selectively deplete the regulatory T cells and enhance the effector T-cell function. 32 We speculated that multitarget therapy can well inhibit the proliferation of T and/or B lymphocytes and can obtain good efficacy. The drug doses used in multitarget therapy is much lower than that used for single target therapy, and the adverse reactions may be reduced. In this meta-analysis, the incidence rates of gastrointestinal syndrome, leucopenia, and irregular menstruation in TAC + MMF + GC group were lower than that in CYC + GC group. The incidence rates of upper respiratory infection, urinary tract infection, and alopecia in TAC + MMF + GC group was lower than those in CYC + GC group. There was no other meta-analysis that assessed this relationship.
In this systematic review, we also included two studies assessing the efficacy and safety of TAC in induction therapy of patients with lupus nephritis. Miyasaka et al 26 conducted a multicenter, double-blind, placebo-controlled study to assess the efficacy and safety of TAC for the treatment of lupus nephritis, and reported that the lupus nephritis disease activity index was decreased in the TAC group and increased in the placebo group. Treatment-related adverse events occurred in 80.0% of the placebo group and 92.9% of the TAC group, but the difference was not significant. Sakai et al 27 conducted a prospective, single-center, single-arm, open-label pilot study, and reported that multitarget therapy with TAC and CYC can be a good therapeutic option for lupus nephritis.
Conclusion
In our meta-analysis, we found that TAC is an effective and safe agent for induction therapy of patients with lupus nephritis. However, more studies are needed to confirm these findings in the future.
